Chief Business Officer at evitria
Mail:
ds@evitria.com
Location:
London, Great Britain
Articles written by Desmond Schofield (54)
-
What is the difference between a monoclonal and a bispecific antibody?
Both monoclonal and bispecific antibodies come with numerous benefits, but have several differences that set them apart. We will review them in this article.

-
HEK293 cells for recombinant antibody production
HEK cells are intensely used in applications like recombinant antibody production. Why? Find out in this article!

-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a […]

-
Why CHO cells remain the first choice for antibody production
In the course of this article, we will explain what makes CHO cells our antibody expression platform of choice.

-
Applications of mammalian cell culture in recombinant antibody production
In this article, we will discuss what makes mammalian cells so popular in rAb production, and explain the process in detail.

-
7 reasons for us to choose Chinese hamster ovary (CHO) cells for recombinant protein production
In this article, we will discuss 7 reasons why we at evitria use CHO cells in recombinant protein production.

-
Recombinant Antibodies – 7 key insights to rAbs
From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.

-
Enhanced purification services for diverse projects
In the dynamic landscape of antibody research and therapeutics, having a diverse array of purification methods is essential. At Evitria AG, we recognize the need for flexibility to meet various project requirements. Let’s delve into our updated purification services.

-
Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.

-
Scalability & Reproducibility – getting it right first time, then again and again…
Delivering material with the same quality at every scale, and with several years in between campaigns, enabled our client to rapidly move through development stages without having to undertake difficult troubleshooting activities or worry about their material quality.
